Cygene Laboratories Enhances Business Model to Address Potential Commercial and Retail Market Demands

ARCHIVED 2002–2016: Originally distributed via the eWire press wire service. Preserved as historical record.

SUBSCRIBE/UNSUBSCRIBE |

Corporate Responsibility

Science & Technology

Syndication Partners

**************************************************************************

E-WIRE PRESS RELEASE E-WIRE PRESS RELEASE E-WIRE PRESS RELEASE

**************************************************************************

For Immediate Release

Cygene Laboratories Enhances Business Model to Address Potential Commercial and Retail Market Demands

CORAL SPRINGS, FLORIDA, Feb. 13 -/E-Wire/-- CyGene Laboratories, Inc. (OTC BB: CYGE.OB) today unveiled an enhanced business model to prepare for the company's introduction of new products and technologies to the consumer, medical and business-to-business sectors. Each of the company's new business divisions will focus on increasing CyGene's ability to compete, creating multiple revenue streams and improving the company's ability to quickly develop, market and license biotechnology-related applications and process technologies.

Under the enhanced business model CyGene's new divisions will include CyGene Research & Development, CyGene Technology & Applications and CyGene Consumer Products & Services.

Â· CyGene Research & Development will create advanced scientific methods and systems for genetic diagnostics and profiling, and pursue partnerships and alliances with universities and research institutions to drive innovation within the biotechnology sector.

Â· CyGene Technology & Applications will develop and license customized solutions for entities in business, government and the biotechnology industry.

Â· CyGene Consumer Products & Services will develop and market branded and private-label products and services for direct and retail distribution to consumers.

Collectively, the divisions will operate in a seamless and highly focused manner to attempt to take advantage of anticipated high demand for genetic profiling and diagnostic products, applications and technologies. CyGene Laboratories, Inc. will serve as the parent operating company to three new divisions.

"The deciphering of the human genome opened a world of opportunity for companies such as CyGene and it is critical that we quickly diversify our organizational structure to meet the strong market demand for advanced consumer and commercial applications and services," said Martin Munzer, chief executive officer of CyGene. "CyGene's enhanced business model will create opportunities for multiple revenue streams and expand our capabilities beyond research so we can take our innovative products and services to market in an accelerated and effective manner."

About CyGene Laboratories, Inc. CyGene Laboratories, Inc., based in Coral Springs, Florida, is a fast-emerging leader in biotechnology application development. The company creates proprietary genetic profiling and diagnostic testing methods for the medical marketplace. Since 1995 CyGene has been developing proprietary and automated DNA and RNA testing systems for the screening, monitoring and diagnosis of human, veterinary and plant diseases. CyGene's proprietary Haystack ProcessingÃ platform supports the highest possible levels of sensitivity and specificity available in the field of molecular diagnostics today. The company has also developed AGENDAÃ, a proprietary automated genomic analysis platform. Visit www.cygenelabs.com.

Forward-Looking Statements The statements made in this press release discussing the creation of advanced scientific methods, development of customized solutions, development of products and service, taking advantage of anticipated demand and taking its products to market are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Additionally words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include, but are not limited to, CyGene's raising sufficient funds to support its development, marketing efforts and corporate overhead, its ability to attract technical employees and the ability of CyGene's management to grow its business with limited assistance. CyGene Laboratories has no duty and undertakes no obligation to update such statements. You should independently investigate and fully understand all risks before making investment decisions.

CyGene Laboratories, Inc.

Martin Munzer, (954) 741-7077, ext. 4403, CyGene Laboratories, Inc.

http://www.cygenelabs.com

**************************************************************************

To Transmit Your News Over E-Wire, visit http://www.ewire.com or

call 1-[REDACTED-PHONE]. E-Wire Is Broadcast To Millions Of Readers Worldwide

**************************************************************************